Biomarker Development and Validation Services

Biomarkers are now central to the advancement of precision medicine, particularly in oncology. They enable a deeper understanding of disease pathophysiology and are instrumental in patient stratification, predicting therapeutic responses, and monitoring clinical progression with enhanced accuracy. As companion diagnostics, biomarkers are essential for identifying patients most likely to benefit from targeted or immunomodulatory therapies.

At CliniSciences, we support your programs by providing access to cutting-edge analytical technologies and proven expertise in biomarker assay development and validation. Our CRO team applies a rigorous and tailored approach to identify, qualify, and validate exploratory or predictive biomarkers, in full compliance with regulatory requirements.

Biomarkers are involved at every stage of the drug development cycle, including:

  • Mechanism of action elucidation

  • Pharmacokinetic/pharmacodynamic (PK/PD) modeling

  • Therapeutic response evaluation

  • Monitoring safety and tolerability

Because methodological robustness is critical, we implement highly sensitive, specific, and reproducible assays, tailored to your biological matrices and scientific goals. The choice of technology (e.g., ELISA, multiplexing, immunohistochemistry, RT-qPCR, NGS) is discussed upfront to ensure reliability, clinical relevance, and regulatory success.

With our network of scientific experts and deep-rooted scientific culture, CliniSciences positions itself as a strategic partner to help transform your biomarker research into actionable tools for therapeutic decision-making.

We can provide:

/upload/sample-preparation-10-bpw2ad.jpg

 

/upload/s-sgtzqn.jpg

 

 

 

/* Style général */ body { font-family: 'Arial', sans-serif; background: #fff; color: #000; margin: 0; padding: 0; } /* Section article */ .article-container { max-width: 1200px; margin: 20px auto; padding: 20px; background: #fff; border-left: 8px solid #fff; } .article-container h2 { color: #006d80; border-bottom: 2px solid #006d80; padding-bottom: 5px; margin-bottom: 20px; font-size: 24px; } .article-container p { font-size: 14px; line-height: 1.6; color: #333; } /* Style des images */ .article-image { text-align: center; margin: 20px 0; } .article-image img { max-width: 100%; height: auto; border-radius: 5px; box-shadow: 0px 2px 10px rgba(0, 0, 0, 0.2); } /* Texte mis en avant */ .highlight { color: #006d80; font-weight: bold; } /* Design responsive */ @media (max-width: 600px) { .article-container { padding: 15px; border-left: 5px solid #006d80; } .article-container h2 { font-size: 22px; } .article-container p { font-size: 14px; } }   The ONCOTARGET Genomic Profiling Panel, a cutting-edge solution designed to revolutionize cancer biomarker detection. ONCOTARGET is a complete NGS panel that we can tailor to your biomarker detection needs. - Key features of Oncotarget - Comprehensive Coverage: The ONCOTARGET panel consists of 1,229 probes targeting 10 oncogenes and the TP53 gene. These probes cover the coding sequences of genes crucial for 1st and 2nd line therapy decisions in metastatic solid cancers. ONCOTARGET kit can be adapted to your needs by adding or deleting areas to be sequenced.    Oncotarget delivers rapid and reliable results from various sample types:   - Fresh or Frozen Tumors: Extract DNA from fresh or frozen tumor tissues. - FFPE Tissues: Analyze DNA from fixed and embedded paraffin-embedded tumors. - Liquid Samples: Detect mutations in plasma, pleural fluid, and cerebrospinal fluid. - Human Cell Lines: Use ONCOTARGET for cell line studies     Cost-Effective Analysis:  With a low sequencing depth (> 80X), ONCOTARGET offers cost-effective profiling without compromising accuracy.     - Gene Targets - - ALK, BRAF, EGFR, ERBB2 (HER2), KIT, KRAS, MAP2K1, MET, NRAS, PDGFRA: Analyze coding exons and splicing zones for solid lung tumors, colorectal tumors, melanoma, and gastrointestinal stromal tumors (GIST). - TP53: Detect mutations associated with cancer susceptibility. - Your biomarker of interest - Clinical Applications - - ONCOTARGET can determine whether or not a patient is eligible for a new treatment as part of a clinical trial.   - ONCOTARGET aids in guiding 1st and 2nd line therapy decisions, allowing clinicians to tailor treatments based on genomic profiles.     - Why chose Oncotarget ?  - - Efficiency: Rapid turnaround time for actionable results. - Affordability: Cost-effective profiling for better patient outcomes - Accuracy: High sensitivity and specificity      Contact our technical support team to explore how we help you.

/* Style général */ body { font-family: 'Arial', sans-serif; background: #fff; color: #000; margin: 0; padding: 0; } /* Section article */ .article-container { max-width: 1200px; margin: 20px auto; padding: 20px; background: #fff; border-left: 8px solid #fff; } .article-container h2 { color: #006d80; border-bottom: 2px solid #006d80;padding-bottom: 5px; margin-bottom: 20px; font-size: 24px; } .article-container p { font-size: 14px; line-height: 1...